|
US4925919A
(en)
*
|
1984-04-25 |
1990-05-15 |
Roland Mertelsmann |
Purified interleukin 2
|
|
US5702699A
(en)
*
|
1982-09-23 |
1997-12-30 |
Cetus Corporation |
Process for the recovery of lipophilic proteins
|
|
US4992271A
(en)
*
|
1982-09-23 |
1991-02-12 |
Cetus Corporation |
Formulation for lipophilic IL-2 proteins
|
|
US4853332A
(en)
*
|
1982-10-19 |
1989-08-01 |
Cetus Corporation |
Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
|
|
JPS60118196A
(ja)
*
|
1983-11-30 |
1985-06-25 |
Takeda Chem Ind Ltd |
インタ−フェロンの製造法
|
|
US4530787A
(en)
*
|
1984-03-28 |
1985-07-23 |
Cetus Corporation |
Controlled oxidation of microbially produced cysteine-containing proteins
|
|
US4569790A
(en)
*
|
1984-03-28 |
1986-02-11 |
Cetus Corporation |
Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
|
|
US4908434A
(en)
*
|
1984-04-25 |
1990-03-13 |
Sloan-Kettering Institute For Cancer Research |
Process for preparing purified interleukin-2
|
|
US4908433A
(en)
*
|
1984-04-25 |
1990-03-13 |
Sloan-Kettering Institute For Cancer Research |
Uses of interleukin-2
|
|
DE3421302A1
(de)
*
|
1984-06-08 |
1985-12-12 |
Hoechst Ag, 6230 Frankfurt |
Verfahren zur isolierung und reinigung von (alpha)-interferonen
|
|
US4572798A
(en)
*
|
1984-12-06 |
1986-02-25 |
Cetus Corporation |
Method for promoting disulfide bond formation in recombinant proteins
|
|
US4748234A
(en)
*
|
1985-06-26 |
1988-05-31 |
Cetus Corporation |
Process for recovering refractile bodies containing heterologous proteins from microbial hosts
|
|
US5248769A
(en)
*
|
1985-06-26 |
1993-09-28 |
Cetus Oncology Corporation |
Process for recovering refractile bodies containing heterologous proteins from microbial hosts
|
|
US4675387A
(en)
|
1985-07-26 |
1987-06-23 |
E. I. Du Pont De Nemours And Company |
Method for extracting protein with organic acid
|
|
US4816440A
(en)
*
|
1985-09-26 |
1989-03-28 |
Cetus Corporation |
Stable formulation of biologically active proteins for parenteral injection
|
|
US5183746A
(en)
*
|
1986-10-27 |
1993-02-02 |
Schering Aktiengesellschaft |
Formulation processes for pharmaceutical compositions of recombinant β-
|
|
US5004605A
(en)
*
|
1987-12-10 |
1991-04-02 |
Cetus Corporation |
Low pH pharmaceutical compositions of recombinant β-interferon
|
|
JP3021040B2
(ja)
*
|
1990-11-23 |
2000-03-15 |
ヘキスト・マリオン・ルセル |
少なくとも1個の分子内ジスルフィド結合を含有する蛋白質を相当する還元された組替え蛋白質を5.0以下のpHで酸化することによって製造する方法
|
|
DE4128319A1
(de)
*
|
1991-08-27 |
1993-03-04 |
Bioferon Biochem Substanz |
Neues rekombinantes human-ifn-beta, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zubereitungen
|
|
FR2686899B1
(fr)
*
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
|
US6399296B1
(en)
*
|
1994-07-20 |
2002-06-04 |
The General Hospital Corporation |
Interaction trap systems for detecting protein interactions
|
|
AU706857B2
(en)
*
|
1995-12-21 |
1999-06-24 |
Genzyme Corporation |
Method for lysing cells
|
|
US7026468B2
(en)
*
|
1996-07-19 |
2006-04-11 |
Valentis, Inc. |
Process and equipment for plasmid purification
|
|
US7807822B2
(en)
|
1996-08-01 |
2010-10-05 |
Robert Bridenbaugh |
Methods for purifying nucleic acids
|
|
AU1275899A
(en)
|
1997-10-24 |
1999-05-17 |
Megabios Corporation |
Methods for preparing polynucleotide transfection complexes
|
|
JPH11335392A
(ja)
*
|
1998-05-26 |
1999-12-07 |
Hsp Kenkyusho:Kk |
可溶性タンパク質の回収方法
|
|
US20050100991A1
(en)
*
|
2001-04-12 |
2005-05-12 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
EP2206720A1
(en)
*
|
2000-04-12 |
2010-07-14 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
WO2002097038A2
(en)
*
|
2001-05-25 |
2002-12-05 |
Human Genome Sciences, Inc. |
Chemokine beta-1 fusion proteins
|
|
AR034749A1
(es)
*
|
2001-07-09 |
2004-03-17 |
Schering Ag |
Formulaciones de interferon beta humano
|
|
EP2261250B1
(en)
*
|
2001-12-21 |
2015-07-01 |
Human Genome Sciences, Inc. |
GCSF-Albumin fusion proteins
|
|
KR101271635B1
(ko)
*
|
2001-12-21 |
2013-06-12 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
알부민 융합 단백질
|
|
AU2002364587A1
(en)
*
|
2001-12-21 |
2003-07-30 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
CA2498518A1
(en)
*
|
2002-09-13 |
2004-03-25 |
Valentis, Inc. |
Apparatus and method for preparative scale purification of nucleic acids
|
|
CA2513213C
(en)
|
2003-01-22 |
2013-07-30 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
WO2005084303A2
(en)
*
|
2004-03-01 |
2005-09-15 |
Enzon Pharmaceuticals, Inc. |
Interferon-beta polymer conjugates
|
|
DE112005000772B4
(de)
*
|
2004-04-07 |
2017-12-28 |
Waters Technologies Corp. (N.D.Ges.D. Staates Delaware) |
Flüssigchromatographiereagenz und Verfahren zum Auftrennen von Enantiomeren
|
|
DE102004047189A1
(de)
|
2004-09-29 |
2006-04-06 |
Robert Bosch Gmbh |
Sensor zur Ortung metallischer Objekte sowie Verfahren zur Auswertung von Messsignalen eines solchen Sensors
|
|
HUE052976T2
(hu)
|
2005-04-11 |
2021-06-28 |
Horizon Pharma Rheumatology Llc |
Urát-oxidáz variáns formái és azok alkalmazása
|
|
CN101622270B
(zh)
*
|
2006-04-12 |
2014-01-01 |
萨文特医药公司 |
用阳离子表面活性剂纯化蛋白质的方法
|
|
JP2010513518A
(ja)
*
|
2006-12-19 |
2010-04-30 |
メリマック ファーマシューティカルズ インコーポレーティッド |
多発性硬化症治療ためのα‐フェトプロテインおよび免疫調節作用物質の同時投与方法
|
|
US8273561B2
(en)
*
|
2007-10-05 |
2012-09-25 |
Nuron Biotech, Inc. |
High pressure treatment of aggregated interferons
|
|
CA2721093A1
(en)
|
2008-04-11 |
2009-10-15 |
Merrimack Pharmaceuticals, Inc. |
Human serum albumin linkers and conjugates thereof
|
|
CA2721870C
(en)
|
2008-04-21 |
2020-12-22 |
Tissue Regeneration Therapeutics, Inc. |
Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents
|
|
CN102282168A
(zh)
*
|
2008-11-18 |
2011-12-14 |
梅里麦克制药股份有限公司 |
人血清白蛋白接头以及其结合物
|
|
WO2010142017A1
(en)
|
2009-06-09 |
2010-12-16 |
Defyrus, Inc . |
Administration of interferon for prophylaxis against or treatment of pathogenic infection
|
|
HUP1200205A3
(en)
|
2009-06-25 |
2012-09-28 |
Savient Pharmaceuticals |
Method and kits for perdicting infusion reaction risk and antibody-mediated low of response by monitoring serum uric acid during pegylated uricare therapy
|
|
US20150202287A1
(en)
|
2012-08-30 |
2015-07-23 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies comprising anti-erbb3 agents
|
|
CN110234340A
(zh)
|
2016-11-11 |
2019-09-13 |
好利恩风湿病制药有限责任公司 |
泼尼松和尿酸酶分子的组合疗法及其用途
|
|
US20200237881A1
(en)
|
2019-01-30 |
2020-07-30 |
Horizon Pharma Rheumatology Llc |
Reducing immunogenicity to pegloticase
|
|
US12121566B2
(en)
|
2019-01-30 |
2024-10-22 |
Horizon Therapeutics Usa, Inc. |
Methods for treating gout
|
|
US12269875B2
(en)
|
2023-08-03 |
2025-04-08 |
Jeff R. Peterson |
Gout flare prevention methods using IL-1BETA blockers
|